HLA-C and neoplasm: Specific targeting of neoepitopes expressed through the major histocompatibility complex (MHC) as an MHC class I/peptide complex (pMHC) can be accomplished with different T cell approaches: autologous tumor-infiltrating lymphocytes expressing endogenous TCRs [12], TCR-engineered T cells [5,13,14,15,16], T cells expressing novel TCRs as the binding domain of the chimeric antigen receptor (TCR CARs) or a TCR-like antibody (TCR-like CARs) [17] (Figure 1).